Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis

Protein Science

Volumn 17, Issue 11, 2008, Pages 1998-2007

  Yoon, Hyesook ^a   Blaber, Sachiko I ^a   Evans, D Michael ^b   Trim, Julie ^c   Juliano, Maria Aparecida ^d   Scarisbrick, Isobel A ^e   Blaber, Michael ^a,f  

^a FLORIDA STATE UNIVERSITY   (United States)

^b Vantia Ltd   (United Kingdom)

^c Ferring Research Ltd   (United Kingdom)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e MAYO CLINIC   (United States)

^f FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Activation cascade; Inflammation; Kallikrein related peptidases; KLK; Plasmin; Thrombin; Thrombostasis

Indexed keywords

HYBRID PROTEIN; KALLIKREIN; PEPTIDASE; PROTEIN KLK; PROTEINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; HUMAN; LIQUEFACTION; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN PURIFICATION; SKIN EXFOLIATION; SPERM;

ENZYME ACTIVATION; FACTOR XA; FIBROBLAST GROWTH FACTOR 1; HUMANS; HYDROLYSIS; KALLIKREINS; PEPTIDE HYDROLASES; PLASMA KALLIKREIN; PLASMIN; RECOMBINANT FUSION PROTEINS; THROMBOSIS;

EID: 55549094116     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.036715.108     Document Type: Article

References (88)

1. Akenami, F.O.T., Siren, V., Wessman, M., Koskiniemi, M., and Vaheri, A. 1999. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J. Neurol. Sci. 165: 71-76.
2. Akiyama, K., Nakamura, T., Iwanaga, S., and Hara, M. 1987. The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett. 225: 168-172.
3. Angelo, P.F., Lima, A.R., Alves, F.M., Blaber, S.I., Juliano, L., and Juliano, M.A. 2006. Substrate specificity of human kallikrein 6: Salt and glycosaminoglycan effects. J. Biol. Chem. 281: 3116-3126.
4. Basham, M.E. and Seeds, N.W. 2001. Plasminogen expression in the neonatal and adult mouse brain. J. Neurochem. 77: 318-325.
5. Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. 2002. Crystal structure and biochemical characterization of human kallikrein 6 reveals a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277: 24562-24570.
6. Blaber, M., DiSalvo, J., and Thomas, K.A. 1996. X-ray crystal structure of human acidic fibroblast growth factor. Biochemistry 35: 2086-2094.
7. Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. 2004. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J. 18: 920-922.
8. Blaber, S.I., Yoon, H., Scarisbrick, I.A., Juliano, M.A., and Blaber, M. 2007. The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry 46: 5209-5217.
9. Borgono, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., and Diamandis, E.P. 2003. Human kallikrein 14: A new potential biomarker for ovarian and breast cancer. Cancer Res. 63: 9032-9041.
10. Brattsand, M. and Egelrud, T. 1999. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 274: 30033-30040.
11. Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. 2005. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124: 198-203.
12. Brosnan, C.F., Cammer, W., Norton, W.T., and Bloom, B. 1980. Protease inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285: 235-237.
13. Campbell, D.J., Dixon, B., Kladis, A., Kemme, M., and Santamaria, J.D. 2001. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R1059-R1070.
14. Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., Yuan, J.J., Petros, J.A., and Andriole, G.L. 1991. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324: 1156-1161.
15. Catalona, W.J., Besser, J.A., and Smith, D.S. 1997. Serum free prostate specific antigen and prostate specific antigen measurements for predicting cancer in men with prior negative prostatic biopsies. J. Urol. 158: 2162-2167.
16. Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. 2004. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122: 1235-1244.
17. Chao, J. and Chao, L. 2006. Experimental therapy with tissue kallikrein against cerebral ischemia. Front. Biosci. 11: 1323-1327.
18. Christensson, A., Laurell, C.-B., and Lilja, H. 1990. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194: 755-763.
19. Citron, B.A., Smirnova, I.V., Arnold, P.M., and Festoff, B.W. 2000. Upregulation of neurotoxic serine proteases, prothrombin, and protease-activated receptor 1 early after spinal cord injury. J. Neurotrauma 17: 1191-1203.
20. Clements, J.A. 1989. The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocr. Rev. 10: 393-419.
21. Clements, J., Hooper, J., Dong, Y., and Harvey, T. 2001. The expanded human kallikrein (KLK) gene family: Genomic organisation, tissue-specific expression and potential functions. Biol. Chem. 382: 5-14.
22. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. 2004. The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41: 265-312.
23. Coombs, G.S., Bergstrom, R.C., Pellequer, J.-L., Baker, S.I., Mavre, M., Smith, M.M., Tainer, J.A., Madison, E.L., and Corey, D.R. 1998. Substrate specificity of prostate-specific antigen (PSA). Chem. Biol. 5: 475-488.
24. Cuzner, M.L. and Opdenakker, G. 1999. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94: 1-14.
25. Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Saeid, M.S., Young, C.Y., Klee, G.G., Tindall, D.J., and Bostwick, D.G. 1999. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53: 939-944.
26. Debela, M., Magdolen, V., Schechter, N., Valachova, M., Lottspeich, F., Craik, C.S., Choe, Y., Bode, W., and Goettig, P. 2006. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 281: 25678-25688.
27. Denmeade, S.R., Lovgren, J., Khan, S.R., Lilja, H., and Isaacs, J.T. 2001. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 48: 122-126.
28. Diamandis, E.P. and Yousef, G.M. 2001. Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev. Mol. Diagn. 1: 182-190.
29. Diamandis, E.P., Yousef, G.M., Luo, L.Y., Magklara, A., and Obiezu, C.V. 2000. The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol. Metab. 11: 54-60.
30. Diamandis, E.P., Okui, A., Mitsui, S., Luo, L.Y., Soosaipillai, A., Grass, L., Nakamura, T., Howarth, D.J., and Yamaguchi, N. 2002. Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res. 62: 295-300.
31. Diamandis, E.P., Scorilas, A., Fracchioli, S., Van Gramberen, M., De Bruijn, H., Henrik, A., Soosaipillai, A., Grass, L., Yousef, G.M., Stenman, U.H., et al. 2003. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 21: 1035-1043.
32. Dihanich, M., Kaser, M., Reinhard, E., Cunningham, D., and Monard, D. 1991. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 6: 575-581.
33. Dong, Y., Kaushal, A., Brattsand, M., Nicklin, J., and Clements, J.A. 2003. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin. Cancer Res. 9: 1710-1720.
34. East, E., Baker, D., Pryce, G., Lijnen, H.R., Cuzner, M.L., and Gveric, D. 2005. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am. J. Pathol. 167: 545-554.
35. Emami, N. and Diamandis, E.P. 2008. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J. Biol. Chem. 283: 3031-3041.
36. Festoff, B.W., Ameenuddin, S., Santacruz, K., Morser, J., Suo, Z., Arnold, P.M., Stricker, K.E., and Citron, B.A. 2004. Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. J. Neurotrauma 21: 907-922.
37. Frenette, G., Tremblay, R.R., Lazure, C., and Dube, J.Y. 1997. Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 71: 897-899.
38. Fuessel, S., Sickert, D., Meye, A., Klenk, U., Schmidt, U., Schmitz, M., Rost, A.K., Eweigle, B., Kiessling, A., and Wirth, M.P. 2003. Multiple tumor marker analyses (PSA, HK2, PSCA, tryp-p8) in primary prostate cancers using quantitative RT-PCR. Int. J. Oncol. 23: 221-228.
39. Gomis-Ruth, F.X., Bayes, A., Sotiropoulou, G., Pampalakis, G., Tsetsenis, T., Villegas, V., Aviles, F.X., and Coll, M. 2002. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J. Biol. Chem. 277: 27273-27281.
40. Gravanis, I. and Tsirka, S.E. 2008. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin. Ther. Targets 12: 159-170.
41. Gveric, D., Hanemaaijer, R., Newcombe, J., van Lent, N.A., Sier, C.F., and Cuzner, M.L. 2001. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain 124: 1978-1988.
42. Hachem, J.P., Wagberg, F., Schmuth, M., Crumrine, D., Lissens, W., Jayakumar, A., Houben, E., Mauro, T.M., Leonardsson, G., Brattsand, M., et al. 2006. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J. Invest. Dermatol. 126: 1609-1621.
43. He, X.-P., Shiosaka, S., and Yoshida, S. 2001. Expression of neuropsin in oligodendrocytes after injury to the CNS. Neurosci. Res. 39: 455-462.
44. Kapadia, C., Yousef, G.M., Mellati, A.A., Magklara, A., Wasney, G.A., and Diamandis, E.P. 2004. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin. Chim. Acta 339: 157-167.
45. Kishi, T., Grass, L., Soosaipillai, A., Shimizu-Okabe, C., and Diamandis, E.P. 2003. Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids. Clin. Chem. 49: 87-96.
46. Klucky, B., Mueller, R., Vogt, I., Teurich, S., Hartenstein, B., Breuhahn, K., Flechtenmacher, C., Angel, P., and Hells, J. 2007. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration and invasion. Cancer Res. 67: 8198-8206.
47. Kumar, A., Mikolajczyk, S.D., Goel, A.S., Millar, L.S., and Saedi, M.S. 1997. Expression of pro-form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57: 3111-3114.
48. Lo, E.H., Wang, X., and Cuzner, M.L. 2002. Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69: 1-9.
49. Lovgren, J., Rajakoski, K., Karp, M., Lundwall, A., and Lilja, H. 1997. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238: 549-555.
50. Lu, W., Bhasin, M., and Tsirka, S.E. 2002. Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J. Neurosci. 22: 10781-10789.
51. Luderer, A., Chen, Y.-T., Soraino, T.F., Kramp, W.J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, K.M., et al. 1995. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of the total prostate-specific antigen. Urology 46: 187-194.
52. Lundstrom, A. and Egelrud, T. 1991. Stratum corneum chymotryptic enzyme: A proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm. Venereol. 71: 471-474.
53. Luo, L.Y., Katsaros, D., Scorilas, A., Fracchioli, S., Bellino, R., van Gramberen, M., de Bruijn, H., Henrik, A., Stenman, U.H., Massobrio, M., et al. 2003. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 63: 807-811.
54. Malm, J., Hellman, J., Hogg, P., and Lilja, H. 2000. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn2+, a tight-binding inhibitor. Prostate 45: 132-139.
55. Memari, N., Jiang, W., Diamandis, E.P., and Luo, L.Y. 2007. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). Biol. Chem. 388: 427-435.
56. Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G.A., and Diamandis, E.P. 2005. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280: 14628-14635.
57. Michael, I.P., Pampalakis, G., Mikolajczyk, S.D., Malm, J., Sotiropoulou, G., and Diamandis, E.P. 2006. Human tissue kallikrein 5 (hK5) is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 281: 12743-12750.
58. Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., Mackenzie, E.T., Vivien, D., and Buisson, A. 2001. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7: 59-64.
59. Oka, Y., Uchida, A., Aoyama, M., Fujita, M., Hotta, N., Tada, T., Katano, H., Mase, M., Asai, K., and Yamada, K. 2005. Expression of myelencephalon- specific protease after cryogenic lesioning of the rat parietal cortex. J. Neurotrauma 22: 501-510.
60. Pampalakis, G. and Sotiropoulou, G. 2007. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 1776: 22-31.
61. Pang, P.T., Teng, H.K., Zaitsev, E., Woo, N.T., Sakata, K., Zhen, S., Teng, K.K., Yung, W.-H., Hempstead, B.L., and Lu, B. 2004. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306: 487-491.
62. Paul, J., Strickland, S., and Melchor, J.P. 2007. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204: 1999-2008.
63. Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. 2008. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283: 12293-12304.
64. Recker, F., Kwiatkowski, M.K., Piironen, T., Pettersson, K., Huber, A., Lummen, G., and Tscholl, R. 2000. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55: 481-485.
65. Robert, M., Gibbs, B.F., Jacobson, E., and Gagnon, C. 1997. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36: 3811-3819.
66. Scarisbrick, I.A., Towner, M.D., and Isackson, P.J. 1997. Nervous system specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J. Neurosci. 17: 8156-8168.
67. Scarisbrick, I.A., Blaber, S.I., Lucchinetti, C.F., Genain, C.P., Blaber, M., and Rodriguez, M. 2002. Activity of a newly identified serine protease in CNS demyelination. Brain 125: 1283-1296.
68. Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. 2006a. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178: 167-176.
69. Scarisbrick, I.A., Sabharwal, P., Cruz, H., Larsen, N., Vandell, A., Blaber, S.I., Ameenuddin, S., Papke, L.M., Fehlings, M.G., Reeves, R.K., et al. 2006b. Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur. J. Neurosci. 24: 1457-1469.
70. Scarisbrick, I.A., Linbo, R., Vandell, A.G., Keegan, M., Blaber, S.I., Blaber, M., Sneve, D., Lucchinetti, C.F., Rodriguez, M., and Diamandis, E.P. 2008. Tissue kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. (in press). doi:abs/10.1515/BC.2008.085.
71. Singh, J., Naran, A., Misso, N.L., Rigby, P.J., Thompson, P.J., and Bhoola, K.D. 2008. Expression of kallikrein-related peptidases (KRP/hK5, 7, 6, 8) in subtypes of human lung carcinoma. Int. Immunopharmacol. 8: 300-306.
72. Sotiropoulou, G., Rogakos, V., Tsetsenis, T., Pampalakis, G., Zafiropoulos, N., Simillides, G., Yiotakis, A., and Diamandis, E.P. 2003. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 13: 381-391.
73. Stamey, T.A., Yang, N., Hay, A.R., McNal, J.E., Freiha, F.S., and Redwine, E. 1987. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 15: 909-916.
74. Takayama, T.K., Fujikawa, K., and Davie, E.W. 1997. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272: 21582-21588.
75. Takayama, T.K., Carter, C.A., and Deng, T. 2001a. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40: 1679-1687.
76. Takayama, T.K., McMullen, B.A., Nelson, P.S., Matsumura, M., and Fujikawa, K. 2001b. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40: 15341-15348.
77. Terayama, R., Bando, Y., Takahashi, T., and Yoshida, S. 2004. Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord. Glia 48: 91-101.
78. Terayama, R., Bando, Y., Yamada, M., and Yoshida, S. 2005. Involvement of Neuropsin in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 52: 108-118.
79. Tsirka, S.E., Gualandris, A., Amaral, D.G., and Strickland, S. 1995. Excitotoxin induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377: 340-344.
80. Vaisanen, V., Lovgren, J., Hellman, J., Piironen, T., Lilja, H., and Pettersson, K. 1999. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis. 2: 91-97.
81. Wagner, S., Kalb, P., Lukosava, M., Hilgenfeldt, U., and Schwaninger, M. 2002. Activation of the tissue kallikrein-kinin system in stroke. J. Neurol. Sci. 202: 75-76.
82. Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S.I., Rodriguez, A., Kogot, J.M., Scarisbrick, I.A., and Blaber, M. 2007. Activation profiles and regulatory cascades of the human kallikrein-related proteases. J. Biol. Chem. 282: 31852-31864.
83. Yousef, G.M. and Diamandis, E.P. 2001. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22: 184-204.
84. Yousef, G.M., Magklara, A., and Diamandis, E.P. 2000. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69: 331-341.
85. Yousef, G.M., Kapadia, C., Polymeris, M.E., Borgono, C., Hutchinson, S., Wasney, G.A., Soosaipillai, A., and Diamandis, E.P. 2003a. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim. Biophys. Acta 1628: 88-96.
86. Yousef, G.M., Polymeris, M.E., Grass, L., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgono, C., Harbeck, N., Schmalfeldt, B., Dorn, J., et al. 2003b. Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63: 3958-3965.
87. Zarghooni, M., Soosaipillai, A., Grass, L., Scorilas, A., Mirazimi, N., and Diamandis, E.P. 2002. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin. Biochem. 35: 225-231.
88. Zhang, L., Seiffert, D., Fowler, B.J., Jenkins, G.R., Thinnes, T.C., Loskutoff, D.J., Parmer, R.J., and Miles, L.A. 2002. Plasminogen has a broad extrahepatic distribution. Thromb. Haemost. 87: 493-501.